TransMedics Group, Inc. (TMDX) Operating Margin: 14.85%
Is TransMedics Group, Inc.’s operating margin high or low?
TransMedics Group, Inc.'s operating margin of 14.85% is 135% above its 5-year average of -42.05%, near the high end of its 5-year range (-130.29%–17.93%).
As of Saturday, June 20, 2026. 12.41% above its 12-month average of 13.21%.
TMDX Operating Margin Chart
TMDX Average Operating Margin Chart
TMDX Current vs Average Operating Margin Chart
TMDX Operating Margin Metrics
OPERATING MARGIN
14.85%
OPERATING MARGIN AVG TTM
13.21%
OPERATING MARGIN AVG 3Y
-4.78%
OPERATING MARGIN AVG 5Y
-42.05%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+12.41%
CURRENT VS 3Y AVG
+410.83%
CURRENT VS 5Y AVG
+135.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 14.85% | 13.21% | -4.78% | -42.05% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 5.87% | -8.16% | -10.59% | -4.68% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -114.00% | -136.51% | -118.68% | -103.43% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 9.25% | 10.48% | 12.70% | 14.08% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 1.32% | 4.35% | -1.93% | -10.04% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | -18.13% | -59.22% | -59.52% | -72.58% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 11.77% | 9.13% | 12.39% | 13.51% |
| Baxter International Inc. (BAX)vs › | $10.27B | -2.65% | -1.31% | -6.02% | 0.15% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -2.02% | -7.24% | -2.92% | -1.15% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 12.41% | 13.70% | 16.38% | 21.25% |
Operating Efficiency
Gross Margin
59.1%
Operating Margin
14.8%
TransMedics Group, Inc. Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Operating Margin FAQ
- What is the operating margin for TransMedics Group, Inc. (TMDX)?
- The operating margin for TMDX stock is 14.85%.
- Is TransMedics Group, Inc.'s operating margin high or low?
- TransMedics Group, Inc.'s operating margin of 14.85% is 135% above its 5-year average of -42.05%, near the high end of its 5-year range (-130.29%–17.93%).
- What is the TTM average operating margin for TransMedics Group, Inc. (TMDX)?
- The TTM average operating margin for TMDX stock is 13.21%.
- What is the 3Y average operating margin for TransMedics Group, Inc. (TMDX)?
- The 3Y average operating margin for TMDX stock is -4.78%.
- What is the 5Y average operating margin for TransMedics Group, Inc. (TMDX)?
- The 5Y average operating margin for TMDX stock is -42.05%.
TransMedics Group, Inc. Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2025-12-31 | 17.93% |
| 2024-12-31 | 8.49% |
| 2023-12-31 | -11.89% |
| 2022-12-31 | -33.64% |
| 2021-12-31 | -130.29% |
| 2020-12-31 | -102.91% |
| 2019-12-31 | -125.42% |
| 2018-12-31 | -155.47% |
| 2017-12-31 | -265.79% |
| 2016-12-31 | -370.20% |
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein